Edith Cowan University

Research Online
Research outputs 2022 to 2026
5-1-2022

A cohort comparison study on women in threatened preterm labor
given nifedipine or nifedipine and salbutamol tocolysis in air
medical retrieval
Breeanna Spring Walsh
Edith Cowan University, b.spring@ecu.edu.au

Fergus W. Gardiner
Dianne Bloxsome
Edith Cowan University, d.bloxsome@ecu.edu.au

David Ford
Edith Cowan University, d.ford@ecu.edu.au

Brennen W. Mills
Edith Cowan University, b.mills@ecu.edu.au

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Nursing Midwifery Commons
10.1016/j.amj.2022.02.005
Walsh, B. S., Gardiner, F. W., Bloxsome, D., Ford, D., Mills, B. W., & Laws, S. M. (2022). A cohort comparison study on
women in threatened preterm labor given nifedipine or nifedipine and salbutamol tocolysis in air medical retrieval.
Air Medical Journal, 41(3), p. 298-302. https://doi.org/10.1016/j.amj.2022.02.005
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/725

Authors
Breeanna Spring Walsh, Fergus W. Gardiner, Dianne Bloxsome, David Ford, Brennen W. Mills, and Simon M.
Laws

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks2022-2026/725

Air Medical Journal 41 (2022) 298−302

Contents lists available at ScienceDirect

Air Medical Journal
journal homepage: http://www.airmedicaljournal.com/

Original Research

A Cohort Comparison Study on Women in Threatened Preterm
Labor Given Nifedipine or Nifedipine and Salbutamol Tocolysis in
Air Medical Retrieval
Breeanna Spring Walsh, RN, RM, PostGradDip 1,2,*, Fergus W. Gardiner, PhDMed 1,3,
Dianne Bloxsome, RN, RM, PhD 4, David Ford, MMSc 2, Brennen W. Mills, PhD 2,
Simon M. Laws, PhD 2,5
1

Royal Flying Doctor Service of Australia, Barton, Canberra, Australia
School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
3
The Rural Clinical School of Western Australia, The University of Western Australia, Crawley, Western Australia, Australia
4
School of Nursing and Midwifery, Edith Cowan University, Joondalup, Western Australia, Australia
5
Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia
2

A B S T R A C T

Objective: Women with threatened preterm labor in remote Australia often require tocolysis in the prevention of in-ﬂight birth during air medical retrieval. However, debate exists over the tocolytic choice.
Methods: A retrospective analysis was undertaken on data containing women who required air medical
retrieval for threatened preterm labor within Western Australia between the years 2013 and 2018.
Results: A total number of 236 air medical retrievals were deemed suitable for inclusion; 141 received nifedipine, and 95 women received salbutamol + nifedipine. Tocolytic efﬁcaciousness was reported in 151 cases,
proportionally more (P < .05) from the women who received salbutamol + nifedipine (n = 68, 71.6%) compared with the women who received nifedipine only (n = 83, 58.9%). Those receiving salbutamol + nifedipine
were more likely to suffer maternal tachycardia (n = 87 [91.6%] vs. n = 62 [44.0%]), fetal tachycardia (n = 26
[27.4%] vs. n = 13 [9.2%]), nausea (n = 17 [17.9] vs. n = 5 [3.55%]), and vomiting (n = 12 [12.6%] vs. n = 2 [1.4%]).
Three women who received salbutamol + nifedipine had serious side effects including echocardiographic
changes, chest pain, and metabolic and lactic acidosis.
Conclusion: Salbutamol + nifedipine tocolysis was proven to be more effective than nifedipine only. Although
salbutamol + nifedipine had increased temporary side effects, most were nonsevere and managed in-ﬂight.
© 2022 The Authors. Published by Elsevier Inc. on behalf of Air Medical Journal Associates. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Rural and remote Australians have a higher incidence of social disadvantage and chronic disease prevalence coupled with a lower provision of health care compared with major city areas.1 Women living
in rural and remote areas are reported to have higher incidences of
modiﬁable risk factors, such as tobacco smoking and alcohol
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consumption, and higher rates of diabetes, hypertension, and renal
disease.1 These trends have been linked to adverse pregnancy outcomes, including threatened preterm labor (TPTL), compared with
Australian averages.2 The higher incidences of modiﬁable risk factors
combined with an increased likelihood of TPTL, which is exacerbated
by remoteness, are concerning because preterm birth is linked to an
increased risk for long-term morbidities.1-3 As such, many women
who reside in rural and remote areas with high-risk pregnancies are
advised to relocate to a metropolitan center before the expected birth
date because of a lack of resources and specialized medical expertise,4 such as emergency cesarean services. However, relocation for
many women is challenging, with some requiring emergency
retrieval services.
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The primary aim of preventing TPTL is to delay birth to allow
women to be transferred to an inner-regional or major city hospital.
Outborn neonates (ie, born outside the tertiary setting) have far
worse outcomes than inborn neonates (ie, born in the tertiary setting), including double the rates of stillbirth and neonatal death5 and
long-term cognitive development delays.6 Nifedipine is typically the
ﬁrst drug of choice in TPTL management with the Royal Flying Doctor
Service (RFDS) within Western Australia (WA) followed by intravenous salbutamol if nifedipine alone is ineffective. Salbutamol tocolysis is rarely seen in other Australian or international air medical and
health care providers due to potential signiﬁcant maternal risk factors, such as palpitations, tachycardia, nausea, hypotension, and
headache.3,7 The literature also indicates that tocolysis therapy for
TPTL and ruptured membranes does not improve adverse neonatal
outcomes or time to delivery.8,9 As such, there is debate within the
air medicine sector regarding the usefulness of tocolytic therapy, speciﬁcally that of intravenous salbutamol.
The aim of this study was to compare the efﬁcaciousness of tocolytics in halting TPTL during air medical retrieval (AR), speciﬁcally
between nifedipine only and salbutamol + nifedipine. We also aimed
to determine any potential side effects during AR.
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those who received nifedipine only and those who received
salbutamol + nifedipine. Women who did not receive any tocolytics
or were given salbutamol without nifedipine were excluded from the
study.
Ethics approval was obtained from the Edith Cowan University
Human Research Ethics Committee (ID: 2019-00793) and the RFDS
Clinical Health Research Committee.
Tocolytic Therapy
The typical salbutamol regimen was 5 mg of the drug diluted in
100 mL normal saline administered at a rate of 12 mL/h; for nifedipine, the standard dose was 60 mg orally.
Tocolytic effectiveness was collated and coded from each case
note as effective, partial, or not effective based on the following
criteria:

1. Effective: contractions ceased on palpation.
2. Partial: on palpation, contractions reduced in strength and/or frequency but did not cease despite tocolysis.
3. Not effective: on palpation, no reduction in strength and/or frequency of contractions despite tocolysis.

Materials and Methods
Setting
The Australian state of WA covers 2.5 million km2, which is comparable to one quarter the size of Europe and one quarter the size of
the United States. WA has a population of approximately 2.6 million
people; 79% of people reside in Perth and the area southwest of Perth,
and the remaining 21% of people are widespread across the state.10
The RFDS provides essential air medical and primary health care to
populations who are unable to access specialist care.7
Sample
A retrospective analysis was undertaken on routinely collected
data from a sample of women who required an AR for TPTL from rural
WA between August 26, 2013, and December 23, 2018. TPTL is
deﬁned as the onset of regular painful uterine contractions (at least 1
every 10 minutes), which are associated with an effacement and/or
dilatation of the cervix at under 37 weeks’ gestation (see Figure 1).11
Side effects were collated directly from the case notes when documented by the medical and nursing crew. For example, nausea or
vomiting was coded accordingly. Maternal tachycardia was documented as a heart rate over 100 beats/min. Hypotension was deﬁned
as any maternal systolic blood pressure below 90. Similarly, fetal
tachycardia was coded as any documented fetal heart rate over
160 beats/min.
The inclusion criteria were pregnant women 20 to 36 + 6 weeks’
gestation who received an AR for TPTL. The lower gestation of 20 + 0
weeks was set to ensure no extreme threatened preterm labor transfers were omitted from our study. The exclusion criteria were women
outside the viable preterm neonate age (< 20 weeks’ gestation) and
those not in established or threatened labor. Women in TPTL with an
antepartum hemorrhage were included in the study. Atypically,
unless there is a massive antepartum hemorrhage of greater than
100 mL or symptoms of shock,12 tocolysis is still considered in
RFDS.13
If not contraindicated, cervical dilatation was assessed before the
ﬂight departure. This assessment, which was conducted via a speculum or vaginal examination, was attended either at the referring center or air side in the ambulance or aircraft by the attending ﬂight
nurse or medical ofﬁcer. It is not standard RFDS practice to repeat
vaginal examinations before departure or in ﬂight unless clinically
indicated.13 Women who were determined appropriate for inclusion
(N = 236) were retrospectively divided into 2 intervention groups:

Tocolytic effectiveness was ascertained by the ﬂight nurse
through intermittent abdominal palpation to determine whether
contractions were successfully paused, completely halting labor.
RFDS clinical guidelines within WA advise to commence a trial of
nifedipine for TPTL cases if the woman’s cervix is less than 4 cm
dilated unless contraindicated (eg, large antepartum hemorrhage,
abruption, or fetal death). After this, if the labor persists after 90
minutes or if cervical dilatation is 4 cm or greater, rescue salbutamol
tocolysis is to be started with the awareness of potential risks, including tachycardia, hypotension, tremor, pulmonary edema, hyperglycemia, and hypokalemia.13
Statistical Analysis
Data were analyzed using Excel (Microsoft, Redmond, WA) and
the statistical software package R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). Independent sample t-tests
were used in the comparison of means between the groups, whereas
the chi-square test with odds ratio analysis where appropriate was
used in the comparison of proportions between groups. Statistical
signiﬁcance was determined at P < .05.
Results
Inclusion Criteria
During the study period between 2013 and 2018, there were
1,094 women who required an AR for pregnancy, including 405
(37.0%) for TPTL, by the RFDS within WA. To achieve a representative
sample (95% conﬁdence interval [CI]), we aimed to include a sample
size of at least 197 TPTL patients.
To account for any potential missing clinical information, we
included 324 women, equaling 80.0% of the TPTL total cohort. Each
patient record was included in reverse chronological order until we
achieved the desired representative sample size.
Of the 324 records, 63 retrievals were excluded for being obstetric
retrievals not in TPTL (eg, ruptured membranes). A further 18 TPTL
retrievals were excluded because the women did not require nifedipine therapy or salbutamol + nifedipine therapy. A further 7 women
did not have enough recorded information to determine the course
of events during retrieval. The total number of participants meeting
the study inclusion criteria was 236, including 141 who received
nifedipine and 95 receiving salbutamol + nifedipine (see Figure 1).
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Obstetric retrieval
transfers captured (n=324)
(2013-2018)

Women not in Preterm
Labour with Obstetric
related retrieval transfers
(n=63) Excluded

Further cases excluded due to
-

Not receiving Nifedipine alone or combinaon of
Nifedipine + Salbutamol (n=18)
Insuﬃcient documented informaon to discern
tocolysis events in retrieval (n=7)

Total parcipants meeng study
inclusion criteria (n = 236)
Figure 1. A ﬂow diagram of participant selection.

Pregnancy Characteristics at Time of Retrieval
The mean age of the 236 women included in the study was
27.9 years (standard deviation = 6.1 years), with a signiﬁcantly (P <
.05) younger age in the salbutamol + nifedipine group (mean
age = 26.9 years, SD = 5.5 years) compared with the nifedipine group
(mean age = 28.7 years, SD = 6.4 years, P < .05) Table 1. demonstrates
woman demographics and pregnancy characteristics. There were 88
women who identiﬁed as Aboriginal and/or Torres Strait Islander,
with a signiﬁcantly higher percentage (P = .029) of these women
receiving salbutamol + nifedipine (n = 44, 46.3%) than nifedipine only
(n = 44, 31.2%). The mean gestation during retrieval was 30.6 weeks
(SD = 3.6 weeks), ranging from 30.5 weeks (SD = 3.9 weeks) in the
salbutamol + nifedipine group to 30.8 weeks (SD = 3.3 weeks) in the
nifedipine group.
Cervical dilatation ranged from cervical cerclage and closed to
fully dilated (10.0 cm), with a mean cervical dilatation of 0.9 cm
(SD = 1.5 cm) taken before transport. The salbutamol + nifedipine
group had a signiﬁcantly (P < .05) wider mean dilation of 1.4 cm
(SD = 1.5 cm) compared with 0.5 cm (SD = 0.9 cm) in the nifedipine
group.
There were 147 case notes reporting women who had at least 1
comorbidity, with nonsigniﬁcant (P < .05) differences between the
groups (60 [63.2%] in the salbutamol + nifedipine group and 87
[61.7%] in the nifedipine group). The leading comorbidities included
substance use disorders (n = 31, 21.1%), diabetes mellitus (n = 16,
10.9%), mental and/or behavioral disorders (n = 12, 8.2%), cardiovascular disease (n = 12, 8.2%), and cervical incompetence (also known
as cervical weakness or insufﬁciency) (n = 8, 5.4%). The leading substance use disorders were tobacco smoking (n = 9, 29.0%), cannabis
(n = 9, 21.95%), intravenous drug use (n = 7, 17.1%), and alcohol consumption (n = 6, 14.6%). There were no differences in proportions of
substance use disorders between the salbutamol + nifedipine group
(n = 17, 11.5%) compared with the nifedipine group (n = 14, 9.5%).

Flight Characteristics
The priority of the AR is determined by the medical ofﬁcer who
receives the air medical tasking. It is dependent on the clinical condition of the laboring woman, their location, and the obstetric support
available. There were 7 (3.0%) priority 1 transfers requiring immediate retrieval, 204 (86.4%) priority 2 transfers requiring urgent medical
retrieval, and 25 (10.6%) priority 3 less urgent medical transfers.14 A
higher
mean
severity
score
was
evident
in
the
salbutamol + nifedipine group (priority 1 = 6.3%, priority 2 = 90.5%,
and priority 3 = 3.15%) versus the nifedipine group (priority 1 = 0.7%,
priority 2 = 83.7%, and priority 3 = 15.6%). The
salbutamol + nifedipine group was more likely (P = .003; odds ratio
[OR] = 2.2; 95% CI, 1.31-3.81) to have both a ﬂight nurse and a medical ofﬁcer (n = 56, 59.6%) compared with the nifedipine group (n = 56,
39.7%). There were no differences in cabin altitude, ambient altitude,
or the time traveled between salbutamol + nifedipine tocolysis versus
nifedipine-only tocolysis transfers.

Tocolytic Effectiveness and Side Effects
Of the total of 236 women included in this study, there were 151
cases of tocolytic effectiveness. Effective tocolysis was signiﬁcantly
more likely (OR = 1.76; 95% CI, 1.01-3.07; P = .046) in the
salbutamol + nifedipine group (68/95 effective, 71.6%) compared
with the nifedipine group (83/141 effective, 58.9%). The
salbutamol + nifedipine group was more likely to suffer from maternal tachycardia (n = 87 [91.6%] vs. n = 62 [44.0%]; OR = 13.86; 95% CI,
6.25-30.74; P < .001), fetal tachycardia (n = 26 [27.4%] vs. n = 13
[9.2%]; OR = 13.86; 95% CI, 6.25-30.74; P < .001), nausea (n = 17
[17.9%] vs. n = 5 [3.55%]; OR = 5.93; 95% CI, 2.11-16.69; P < .001), and
vomiting (n = 12 [12.6%] vs. n = 2 [1.4%]; OR = 10.05; 95% CI, 2.1946.01; P < .001). Of these, 3 women developed signiﬁcant side effects
after salbutamol. These included 2 women who suffered cardiac
effects of chest pain with associated electrocardiographic changes
(case A: ST depression lead I, II, and III and Augmented Vector Foot
(AVF) and ST-elevation Augmented Vector Right (AVR); case B: ﬂat
lead II, III, and ST depression V4-V6) despite no previous cardiac history. The third woman developed severe metabolic and lactic acidosis, which was managed in ﬂight. The results conﬁrmed a woman
developing severe complications after salbutamol + nifedipine therapy was less than 2% (1.18%) compared with no cases in the nifedipine group.

Antepartum Hemorrhages and Threatened Preterm Labor
Twenty cases (8.47%) reviewed had a small amount of bleeding
and were not contraindicated to receive tocolytic therapy because
transport to higher medical care was prioritized. Twelve of these
women were given nifedipine + salbutamol, and 8 received nifedipine only. Gestation ranged from 22 + 6 weeks to 33 + 4 weeks. Cervical dilatation ranged from closed to fully dilated during transfer. All
but 2 cases were effectively tocolyzed. Of the 2 women who continued to labor in ﬂight, the ﬁrst ﬂight was a duration of 1 hour 5
minutes; nifedipine was ineffective, and salbutamol was not commenced. The woman started involuntarily pushing on landing in
Perth, was assessed to be fully dilated, and continued en route to a
tertiary hospital via a priority 1 road ambulance. The second woman
received nifedipine and then salbutamol, which caused signiﬁcant
maternal tachycardia and was ceased accordingly. Contractions continued regularly in ﬂight, again a short ﬂight duration of 28 minutes
within the southwest region of WA. Women in TPTL diagnosed with
an antepartum hemorrhage typically suffered from tachycardia and
tachypnea after tocolysis in ﬂight. These symptoms did not cause further clinical distress or deterioration.
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Table 1
Preterm Labor Maternal Characteristics and Effectiveness of Salbutamol and Nifedipine Compared With Nifedipine-Only Therapy
Description
Total preterm labor population (%)
Mother characteristics
Mean age in years (SD)
Mean weight in kg (SD)
Number Indigenous (%)
Number non-Indigenous (%)
Missing Indigenous status (%)
Drug and alcohol use during current pregnancy (%)
At least 1 comorbidity at retrieval (%)
Pregnancy characteristics
Mean gestation in weeks (SD)
Mean parity (SD)
Mean gravida (SD)
Mean initial assessment of cervical dilatation in cm (SD)
Flight characteristics
Tasking priority 1 (%)
Tasking priority 2 (%)
Tasking priority 3 (%)
Number of FNs (%)
Number of MOs (%)
Number of FNs + MOs (%)
Maximum cabin altitude in feet (SD)
Maximum ambient altitude in feet (SD)
Tocolytic effectiveness
Number not effective: on palpation, no reduction in strength and/or frequency of
contractions despite tocolysis (%)
Number partially effective: on palpation, contractions reduced in strength and/
or frequency but did not cease despite tocolysis. (%)
Number effective: contractions ceased on palpation (%)
Tocolytic side effects (%)
Maternal tachycardia
Fetal tachycardia
Hypotension
Nausea
Vomiting
Chest pain
Metabolic acidosis

Total Population
236

Salbutamol + Nifedipine
95 (40.2)

Nifedipine Only
141 (59.75)

27.89 (6.081)
75.92 (16.506)
88 (37.3)
136 (57.6)
12 (5.1)
41 (17.4)
147 (62.3)

26.91 (5.51)
76.49 (18.93)
44 (46.3)a
48 (50.5)
3 (3.2)
24 (25.3)a
60 (63.2)

28.67 (6.41)a
75.81 (15.21)
44 (31.2)
88 (62.4)
9 (6.4)
17 (12.1)
87 (61.7)

30.58 (3.626)
1.58 (1.644)
3.15 (2.034)
0.9 (1.457)

30.53 (3.92)
1.53 (1.45)
3.13 (1.97)
1.40 (1.51)a

30.84 (3.34)
1.63 (1.64)
3.27 (2.07)
0.48 (0.93)

7 (3.0)
204 (86.4)
25 (10.6)
123 (52.1)
1 (0.4)
112 (47.4)
5,474.01 (2,117.25)
20,452.08 (5,538.454)

6 (6.3)
86 (90.5)
3 (3.2)
38 (40.0)
1 (1.5)
56 (59.6%)
5,786 (1,802)
20,955 (4,762)

1 (0.7)
118 (83.7)
22 (15.6)
85 (60.3)a
0 (0.0)
56 (39.7%)
5,301 (2,275)
20,107 (5,920)

25 (10.6)

11 (11.6)

60 (25.4)

16 (16.8)

14 (9.9)
44 (31.2)

151 (64.0)

68 (71.6)

a

83 (58.9)

149 (63.1)
39 (16.5)
17 (7.2)
22 (9.3)
14 (5.9)
2 (0.8)
1 (0.4)

87 (91.6)b
26 (27.4)b
9 (9.5)
17 (17.9)b
12 (12.6)b
2 (0.8)
1 (0.4)

62 (44.0)
13 (9.2)
8 (5.7)
5 (3.55)
2 (1.4)
0 (0.0)
0 (0.0)

FNs = ﬂight nurses; MOs = medical ofﬁcers; SD = standard deviation.
a
P < .05.
b
P < .001.

Discussion
Despite tocolysis occurring at various times in the ﬁrst stage of
labor with progressing labors and unsuccessful nifedipine tocolysis,
rescue tocolysis with salbutamol proved efﬁcacious. As per other air
medical research,1,15,16 we found that no preterm births occurred in
ﬂight using salbutamol + nifedipine rescue tocolysis. Unlike Akl and
colleagues15 who reported no signiﬁcant complications with salbutamol tocolysis, our study uncovered 3 women who developed marked
side effects after salbutamol use. This difference could be due to the
women in Akl et al’s study15 indicating that recently retrieved
women have higher rates of reported chronic disease and pregnancy
risk factors.1,17
The results of our study identiﬁed that severe complications after
salbutamol + nifedipine therapy were rare. These ﬁndings are essential in the prevention of remote preterm births for practitioners who
are not currently using salbutamol tocolysis for the treatment and
management of TPTL. Martin et al18 undertook a study over a 3-year
period in the Northern Territory of Australia; they reported nifedipine-only tocolysis resulted in only 3 in-ﬂight births out of a total
sample size including 304 cases. The signiﬁcant differences of inﬂight birth rates reported by Martin et al,18 the same as were found
in our study, indicate rescue salbutamol should be considered for the
management and treatment of TPTL in remote locations across Australia and arguably globally with the urgent need to standardize TPTL
practice management.

Because of the potential for adverse implications in women with
existing heart disease, namely rheumatic heart disease (RHD), which
is noted to be common in remote Australia,19 practitioners may be
reluctant to use beta-agonists. Unfortunately, our research did not
verify safety for women with RHD because only 2 women were
reported to suffer from RHD, and neither required salbutamol tocolysis. Another 2 women suffered from heart disease; 1 did not receive
salbutamol, and the other developed severe complications of metabolic acidosis. RFDS clinical guidelines encourage caution with cardiovascular disease and salbutamol use.20 Despite no available
research on salbutamol use with women who suffer from heart disease who are in TPTL, 1 study (the BALTI-2 [Beta-Agonist Lung Injury
Trial-2] study) demonstrated beta-agonist use in critical illness can
potentially exacerbate myocardial injury and cardiac failure.21 The
study was ceased midtrial in the treatment of acute respiratory distress syndrome with a 7-day continuous infusion of salbutamol due
to a signiﬁcant rise in mortality. This is as close as a comparison available for beta-agonist use in the emergency retrieval setting where
infusions last from 30 minutes up to 12 hours on average in WA. As
discussed previously, the ﬁndings from the BALTI-2 study are alarming and indicate the need for further research in the air medical use
of salbutamol tocolysis in women with TPTL and cardiovascular
disease.21
In our study, the incidence of metabolic changes secondary to salbutamol was scarce. Two cases demonstrated women who suffered
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hypokalaemia requiring supplementation, and a further 2 were diagnosed with hyperglycaemia. Routine blood glucose and potassium
levels were not checked each ﬂight; therefore, it is anticipated that
further metabolic changes may have been found with greater blood
analysis in ﬂight. Many variables, including infusion duration, were
outside the scope of this research. These variables warrant additional
research to ascertain the safest, yet most effective dosage, minimizing
side effects in tocolysis for the treatment of TPTL in ﬂight.
Women who identiﬁed as Aboriginal and Torres Strait Islander
had higher comorbidities and higher modiﬁable risk factors, including alcohol and tobacco consumption during pregnancy, and were
more likely to progress to needing salbutamol + nifedipine tocolysis.
These ﬁndings suggest a link between comorbidities; drug and alcohol use; and progressive, resistant TPTL in the Aboriginal and Torres
Strait Islander population. This knowledge can be used for air medical
clinicians to anticipate the need for more aggressive tocolysis if the
woman in TPTL has comorbidities, partakes in drug or alcohol use, or
is of Aboriginal or Torres Strait Islander decent.
Our ﬁndings also determined women who received
salbutamol + nifedipine were more likely to have a higher severity,
which resulted in a ﬂight nurse and a medical ofﬁcer being tasked
rather than a solo ﬂight nurse. The higher priority and multicrew
tasking with salbutamol + nifedipine shows it is more likely to be
used in complex progressing TPTL cases in which aggressive tocolysis
is required under judicious advanced care to ensure maternal and
fetal safety is maintained while achieving in utero air medical transfer.
Women most likely to beneﬁt from the use of a tocolytic drug are
those who are very preterm or women who have not yet completed a
full course of corticosteroids. The National Institute of Clinical Excellence stated that tocolytic therapy is contraindicated in placental
abruption and is “relatively contraindicated” in “mild hemorrhage”
due to placenta previa.12 Our study reviewed 20 women who were
tocolyzed with small antepartum bleeds associated with TPTL. The
common side effects found were tachycardia and tachypnea. No further clinical deterioration occurred after these side effects. Our
research supports tocolysis use when TPTL is associated with a small
antepartum hemorrhage with successful tocolysis and manageable
side effects. For extremely premature born neonates, 20% have a
maternal diagnosis of TPTL and Antepartum Haemorrhage (APH).12
In addition to this, there is a known correlation between extreme
prematurity, APH, and cerebral palsy.12 Our study demonstrates
women with a small APH in TPTL can be safely tocolyzed to facilitate
expectant birth care. This may also include the use of corticosteroids,
which has been proven to reduce rates of cerebral palsy and morbidity in extreme premature neonates.4,6
There were a number of limitations in this study. We did not collect patient hospital outcomes, such as gestational age at birth, mode
of birth, special care nursery admission, birth weight, resuscitation,
and stillbirth rates. Further research is required to identify the impact
of tocolysis postretrieval when the woman reaches deﬁnitive care.
Furthermore, we analyzed a subset of RFDS data collected between
2013 and 2018, meaning the data were not exhaustive of all cases
between this period.
Conclusion
Our ﬁndings demonstrate rescue salbutamol tocolysis to be efﬁcacious. Women residing in remote locations in TPTL are at risk of preterm birth and must be considered suitable candidates in receiving

rescue salbutamol. Acknowledgment and caution must be given with
temporary side effects of maternal nausea, vomiting, and maternal
and fetal tachycardia possible. A reduction in remote preterm birth
rates and improved neonatal outcomes could potentially be achieved
using the RFDS salbutamol tocolytic regimen for air medical TPTL
transfers. These ﬁndings are transferrable in AR services where pregnant women are ﬂown over large distances.
Additional in-ﬂight research is needed to determine the effects for
women with pre-existing cardiac disease receiving salbutamol tocolysis. Maternal and neonatal outcomes could be improved with
aggressive salbutamol tocolysis throughout the Northern Territory of
Australia if proven to be safe to use in women with RHD. Similarly,
postpartum outcomes secondary to in-ﬂight TPTL tocolysis would be
invaluable, particularly in pertaining to hemorrhage and infection
rates.
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